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Background: Immunity to malaria requires innate, adaptive immune responses and Plasmodium-specific memory
cells. Previously, mice semi-immune to malaria was developed. Three cycles of infection and cure (‘three-cure’) were
required to protect mice against Plasmodium berghei (ANKA strain) infection.
Methods: C57BL/6 J mice underwent three cycles of P. berghei infection and drug-cure to become semi-immune.
The spleens of infected semi-immune mice were collected for flow cytometry analysis. CD11c(+) cells of semi-
immune mice were isolated and transferred into naïve mice which were subsequently challenged and followed up
by survival and parasitaemia.
Results: The percentages of splenic CD4(+) and CD11c(+) cells were increased in semi-immune mice on day 7
post-infection. The proportion and number of B220(+)CD11c(+)low cells (plasmacytoid dendritic cells, DCs) was
higher in semi-immune, three-cure mice than in their naïve littermates on day 7 post-infection (2.6 vs 1.1% and
491,031 vs 149,699, respectively). In adoptive transfer experiment, three months after the third cured P. berghei
infection, splenic CD11c(+) DCs of non-infected, semi-immune, three-cure mice slowed Plasmodium proliferation
and decreased the death rate due to neurological pathology in recipient mice. In addition, anti-P. berghei IgG1 level
was higher in mice transferred with CD11c(+) cells of semi-immune, three-cure mice than mice transferred with CD11c(+)
cells of naïve counterparts.
Conclusion: CD11c(+) cells of semi-immune mice protect against experimental cerebral malaria three months after the
third cured malaria, potentially through protective plasmacytoid DCs and enhanced production of malaria-specific
antibody.
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Immunity to malaria in humans is a step-wise process that
spans invasion of sporozoites into the body to development
of erythrocytic parasites. This process involves humoral and
cellular responses of innate immune cells (e.g., macrophages,
dendritic cells (DCs)) and adaptive IFN-γ-producing CD4(+)
and CD8(+) T cells [1]. Malaria infection at the individual
and community levels is affected by acquired immunity.
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persons often can be infected by malaria but rarely manifest
the typical severe symptoms [2].
Memory immune cells are necessary to maintain im-
munity to microbial pathogens. The presence of Plasmo-
dium-specific memory T and B cells in people living in
malaria-endemic areas has been reported [3,4]. In a mouse
model, memory CD4(+) T cells from chronically infected
mice were shown to effectively delay and reduce para-
sitaemia and pathology [5]. In addition, memory CD8(+)
T cells specific for Plasmodium liver-stage antigens prolong
protection against malaria [4]. Coincidentally, both anti-
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transmission rates are stably maintained over time in
the absence of re-infection [3,6,7].
CD11c(+) DCs are a major population of antigen-
presenting cells that mediate interactions between the
innate and adaptive immune responses and play an im-
portant role at the host-pathogen interface, including in
responses to Plasmodium parasites [8-11]. Pattern rec-
ognition receptors expressed by DCs, such as toll-like
receptors (TLRs), nod-like receptors, and C-type lectins,
recognize distinct conserved microbial molecules [12].
DC maturation is critical in immunity to pathogenic
micro-organisms because of the potential of these cells
to stimulate differentiation of naïve CD4(+) T cells into
various T helper (Th) cell types, including Th1, Th2,
Th17, follicular Th cells, and induced regulatory T cells
[13,14]. However, DC function can be compromised dur-
ing the blood stage of malaria infection, as evidenced by
the observation that Plasmodium falciparum-infected
red blood cells adhere to human DCs via interaction be-
tween P. falciparum erythrocyte membrane protein 1
(PfEmP1) and CD36, thus inhibiting DC maturation and
subsequently reducing the capacity of DCs to stimulate
T cells [15,16]. However, the anti-malarial function of
DCs in repeatedly malaria-infected hosts and the long-
lasting protection of these cells remain unknown. This is
the first study to show that CD11c(+) DCs from mice
semi-immune to malaria contribute to the prolonged
suppression of Plasmodium growth in the blood stage
and prevent neurological pathology.
Methods
Animals and infection
C57BL/6 J (B6) mice aged six to eight weeks were supplied
by SLC Laboratories, Fukuoka, Japan. Semi-immune mice
were generated as described elsewhere [17,18]. Briefly,
C57BL/6 mice were infected with 104 PbA-pRBCs and
then treated on day 5 after infection with intra-peritoneal
injection of chloroquine (20 mg/kg/day) and pyrimeth-
amine (20 mg/kg/day) daily for 7 days. Before subsequent
rounds of infection, the parasite-clearance was confirmed
and mice were rested for two weeks and then re-
challenged with 104 PbA-pRBCs. Mice that underwent
three cycles of drug-cured infection became semi-immune.
Challenge infections were performed by intraperitoneal in-
jection of 105 Plasmodium berghei (ANKA strain) infected
RBCs (iRBCs). Plasmodium berghei was selected for its
capacity to induce experimental cerebral malaria (ECM) in
B6 mice, with neurological signs (ataxia, paralysis, deviation
of the head, and convulsions) appearing six to ten days after
infection [19]. Three to four months after the third cured
infection, semi-immune mice and age-matched controls
were finally challenged with 105 P. berghei-iRBCs without
subsequent treatment.Approval from the local ethics committee for animal
care and research was obtained, and all laboratory and
animal practice guidelines of the Animal Centre of the
Institute of Tropical Medicine (NEKKEN), Nagasaki,
Japan, were adhered to. All experiments were conducted
in accordance with local Animal Ethics Committee
regulations (Ethical Review Committee at Institute of
Tropical Medicine Nagasaki University).
Flow cytometry
Spleen cells were collected and stained for cell surface
antigens. Splenocytes were incubated on ice for 30 min
with fluorochrome-conjugated mAbs against surface an-
tigens. The mAbs used were anti-CD4 PE-cy7, CD8 FITC,
CD19 Percp-cy5.5, CD11c APCs, CD11c APC-cy7, B220
PE-cy7, and isotype control Abs (BD Biosciences). Flow
cytometric analysis was conducted using FACS Calibur,
FACSCanto II, or FACSVerse systems (BD Biosciences),
and the resulting data were analysed using Flow Jo
software (Tree Star, Inc).
Adoptive transfer
Three to four months after the third cured infection,
non-infected, semi-immune and age-matched naïve B6
mice were sacrificed. Spleens were harvested and ho-
mogenized in collagenase D, and the resulting homoge-
nates were resuspended in PBS, pH 7.2. After incubation
with 25 μl of anti-CD11c microbeads (Miltenyi Biotec),
225 μl of cell suspension from one spleen was first
sorted for positive selection. The purity of the CD11c(+)
fraction was >95%. A total of 106 CD11c(+) cells from
either of semi-immune or naïve mice were intraven-
ously adoptively transferred into six- to eight-weeks-old
naïve B6 mice 24 hours before malaria infection with
105 P. berghei-iRBCs. Naïve control mice were injected
with 200 μL of phosphate buffer saline (PBS). Parasit-
aemia was monitored daily by Giemsa-staining of thin
blood smears from day 1 to day 8 post-infection and
then every three to four days, and the degree of para-
sitaemia was expressed as a percentage determined
from examination of more than 1,000 RBCs. Mice in
each group were monitored daily for symptoms of ECM,
such as coma, convulsions, lethargy, tremors, ataxia,
hemiplegia, and paraplegia.
ELISA
Plasma harvesting and measurement of plasma P. berghei-
specific IgG subtypes were conducted as described in a
previous study [17]. The entire set of experiments was
performed at least twice.
Results
This is the first study demonstrating that splenic CD11c(+)
cells from semi-immune mice are capable of prolonged
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of ECM. This semi-immune mouse model was developed
by repeated infection and radical anti-malaria treatment,
mimicking the natural boost infection and recovery in
humans in areas of intense P. falciparum transmission. In
previous work, it was shown that mice that undergo three
cycles of infection and cure retain resistance to ECM
12 months after the third exposure to malaria.
A history of malaria exposure increased the population
of CD4(+), CD11c(+), B220(+)CD11c(+)low cells and the
size of CD11c(+)hi cells in semi-immune mice on day 7
post-infection
It was found that the percentage of splenic CD4(+) and
CD11c(+) cells in semi-immune mice on day 7 post-
infection was significantly higher than in infected naïve
counterparts (Figure 1A), suggesting a potentially protect-
ive cooperation of CD4(+) and CD11c(+) cells against
Plasmodium infection. Meanwhile, no significant differ-
ence in proportion of CD8(+) cells was observed between
these two groups of mice (Figure 1A). Thus, this study
was carried out with the hypothesis that CD11c(+) cells
from semi-immune mice contributed to immunity against
ECM. In murine malaria infection, splenic CD11c(+) cells
are considered as splenic CD11c(+) DCs [20]. The role of
DCs in prolonged suppression against malaria is still un-
clear. Hence, the anti-malaria capacity of CD11c(+) DCs
and their subtypes was investigated from semi-immune
mice in long term after the last immunization. B220(+)
CD11c(+)low cells, named as plasmacytoid DCs [21,22],
play a critical role in immunity to malaria [21] and in im-
proving the function of conventional DCs [23]. The distri-
bution of this DC subtype in the spleen of semi-immune
mice was, therefore, examined. Three months after the
third cured malaria infection, B220(+)CD11c(+)low cells
in CD19(−) gate accounted for a significantly higher per-
centage and showed a greater number of cells on day 7
post-infection in infected semi-immune mice than in naïve
littermates (2.6 and 1.1%; 491,031 and 149,699, respect-
ively; P < 0.05) (Figure 1B). Meanwhile, no differences in
the proportion or number of B220(−)CD11c(+)hi cells
(conventional DCs) was observed between these two
groups (1.3 and 1.4%; 222,096 and 127,144, respectively)
(Figure 1B). The increase in the proportion of plasmacytoid
DCs in semi-immune mice probably enhanced the activa-
tion of conventional DCs and, therefore, stimulated the
proliferation of T cells, leading to parasite clearance.
The precise role of plasmacytoid DCs remains unclear.
There is, however, growing evidence that the role of
plasmacytoid DCs is to support and improve the func-
tion of conventional DCs [23]. In non-lethal Plasmo-
dium chabaudi infections, the numbers of both splenic
plasmacytoid and conventional DCs are increased, but
only conventional DCs upregulate the expression ofco-stimulatory molecules and present Plasmodium an-
tigens, resulting in activation of CD4(+) T cells [24,25].
A recent mouse model study showed that up to 70% of
plasmacytoid DCs in the spleen had been in contact
with Plasmodium spp. and that a small percentage of
these cells were reservoirs of infectious parasites [20].
Significantly, interaction between CD40 on conventional
DCs and the CD40 ligand on plasmacytoid DCs leads to
IL-12 production by conventional DCs, inducing immune
activation [26]. The function of plasmacytoid DCs in mal-
aria should be confirmed in a future study.
In addition, it was found that CD11c(+)hi cells (conven-
tional DCs) were larger in size on day 7 post-infection in
semi-immune mice than naïve counterparts, with forward
scatter relative median sizes of 517 and 456, respectively
(P < 0.05) (Figure 1C). There was no difference in the size
of CD11c(+)hi cells on day 0 in these two groups of mice
(Figure 1C). The increased size of conventional CD11c(+)
hi DCs in the semi-immune mice probably played a role
in the beneficial effects of these DCs in the host’s immune
response to the parasites, as increases in the size of im-
mune cells during malaria infection have been reported.
For example, the size and granularity of splenic DCs were
shown to increase in mice with malaria [27]. Immature
DCs are much smaller in size than mature DCs [28];
therefore, the increased size of CD11c(+)hi conventional
DCs observed in this study could have functional rele-
vance for immunity against malaria.
Naïve B6 mice receiving splenic CD11c(+) cells from
donor semi-immune mice exhibited lower parasitaemia
and were partially protected from development of ECM
during the acute phase of malaria infection
To examine the long-lasting anti-malaria role of splenic
CD11c(+) DCs derived from semi-immune mice, CD11c(+)
cells was isolated with the purity >95% (Figure 2A) from
the spleens of semi-immune mice three to four months
after the third cured infection, as well as from age-matched
naïve controls and passively transferred these cells to eight-
weeks-old naïve mice. As shown in Figure 2B, 61% of mice
receiving CD11c(+) cells from semi-immune mice (SI11c)
were resistant to ECM and survived for 14 days post-
infection. Finally, all of these mice succumbed to se-
vere anemia and high parasitaemia around days 28–30
post-infection. Conversely, the survival rates of PBS-
treated control mice and mice that received CD11c(+)
cells from age-matched naïve mice (Na11c) were signifi-
cantly lower during the first two weeks of infection, at
28 and 31%, respectively (P <0.05). Splenic CD11c(+)
DCs from semi-immune mice with last immunization
three months previously partially protected naïve B6
mice against ECM in the passive transfer experiments,
confirming the beneficial effects of CD11c(+) DCs in pro-
longed protection against pathology. CD11c(+) cells from
Figure 1 The proportion of B220(+)CD11c(+)low cells was higher and the size of CD11c(+)hi cells was enhanced on day 7 post-infection
in semi-immune mice challenged three months after the third exposure to malaria. (A) Median percentages of splenic CD4(+), CD8(+) and
CD11c(+) cells on day 7 post-infection (±interquartile range) (n = 6-7 mice/group). (B) Median percentages and number of splenic B220(+)CD11c
(+)low cells and B220(−)CD11c(+)hi cells on day 7 post-infection (±interquartile range) (n = 4 mice/group). Plots show the gating strategy and
data for representatives of these cells on day 7 post-infection in semi-immune and naïve mice. (C) Relative median size of splenic CD11c(+)hi
cells on day 7 post-infection (±interquartile range) (n = 4 mice/group). Representative histograms regarding the size of CD11c(+)hi cells in
semi-immune (black) and naïve (red) mice on day 0 and day 7 post-infection are shown. Data are pooled from two independent experiments
(A, B) or representative of two independent experiments (C). *P < 0.05, Mann–Whitney U test.
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Figure 2 Splenic CD11c(+) cells from semi-immune mice lowered parasitaemia, enhanced anti-P. berghei IgG1 level and improved the
ECM survival rate in recipient mice. (A) Plots show the representative purity of CD11c(+) cells. (B) Survival curves for mice that received 106
splenic CD11c(+) cells and for PBS-treated control mice (n = 16-18 mice/group). Data shown are pooled from three independent experiments.
Significant differences between groups as determined by log-rank test are indicated by symbols: *P < 0.05 for SI11c vs Na11c; $P < 0.05 for
SI11c vs PBS. (C) Bar chart showing the median parasitaemia (%) of recipient mice over the time of infection (n = 6-9 mice/group). Parasitaemia
(%) of these groups of mice was performed on days post challenge as indicated and was shown by the box-plots. Data shown are representative of
three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001, Mann–Whitney U test. (D) Median levels of plasma anti-P. berghei IgG1, IgG2a and
IgG2b were determined on day 5 post-infection in mice with adoptively transferred DCs. Data are representative of two separate experiments (n = 4
mice/group). *P < 0.05, Mann–Whitney U test.
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parasitaemia in recipients beginning on day 5 post-infection
compared with PBS-treated control mice and those thatreceived CD11c(+) cells from naïve mice (Figure 2C). It is
known that in malaria infection, DCs containing RBCs
expressed higher type I interferon[IFN] levels than those
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immune mice, including RBC containing DCs, probably ex-
tendedly produced more type I IFN than naïve DCs and
then suppressed the parasite proliferation. Consequently,
DCs could be one of effective cells for low parasitaemia
which was previously observed in semi-immune mice [17].
Prevention of ECM through a lowering of parasitaemia cor-
related with reduced levels of pathogenic cytokines, chemo-
kines, CD8(+) T cells, and parasites in the brain has been
reported [29-31]. Hence, in the present study, the decrease
in parasitaemia mediated by semi-immune DCs probably
contributed to the improved survival rate of recipient mice
during the acute phase of malaria. CD11c(+) DCs, major in-
nate immune cells, are important in the development of
immunity to malaria. Previous studies in mice have
demonstrated that in malarial infections that prove le-
thal, the function of DCs is compromised, but func-
tional DCs improve the survival rate in non-lethal
malaria [23,32-35].Donor CD11c(+) cells from semi-immune mice induced
anti-P. berghei IgG1 antibody production in recipient mice
during the acute stage of infection
To identify the type of immune response provoked in
mice receiving transferred cells, the levels of plasma IgG
subclasses specific to malaria were measured. The level
of helper type 2 T cell (Th2)-mediated anti-P. berghei
IgG1 production [36] in semi-immune CD11c(+) cell-
treated mice was significantly enhanced compared with
naïve CD11c(+) cell-treated mice (P < 0.05). Similar
production of helper type 1 T cell (Th1)-mediated
Plasmodium-specific IgG2a and IgG2b [36] was observed
in all three mouse groups (Figure 2D). Although the dif-
ference was not significant, the P. berghei-specific IgG1
level was higher in mice that received semi-immune
CD11c(+) cells than in PBS-treated controls (Figure 2D).
These data indicate that Th2 activation via IL-4, Il-5 or
IL-13 could be associated with downstream signalling by
protective semi-immune DCs. The signalling pathway of
semi-immune DCs should be studied further in the
future.Conclusion
Protective CD11c(+) DCs from malaria-exposed mice
survive for extended periods, despite the absence of fur-
ther exposure to malaria. These cells prevent develop-
ment of ECM and lower the degree of parasitaemia.
Full elucidation of the role of Plasmodium-exposed
CD11c(+) DCs and plasmacytoid DCs in malaria and
other infectious diseases requires further study. The
findings of the present study may provide the back-
ground necessary to prolong the protective immuno-
genicity of potential vaccine candidates.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KH and LQB designed the study, coordinated the experiments, and wrote
the manuscript; LQB, DMN and MK performed the experiments and analysed
the data. All authors commented on and contributed to writing the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by the Global Centre of Excellence (GCOE),
Nagasaki, Japan (to KH (2008–2012)) and Health and Labour Science
Research Grants (H25-Kokui-Shitei-001).
Author details
1Department of Immunogenetics, Institute of Tropical Medicine, Nagasaki
University, Nagasaki, Japan. 2Department of Clinical Product Development,
Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan. 3Centre
for International Collaborative Research, Nagasaki University, Nagasaki, Japan.
4Animal Research Centre for Tropical Infections, Institute of Tropical
Medicine, Nagasaki University, Nagasaki, Japan. 5Department of Parasitology,
Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
Received: 20 October 2014 Accepted: 26 December 2014
References
1. Riley EM, Stewart VA. Immune mechanisms in malaria: new insights in
vaccine development. Nat Med. 2013;19:168–78.
2. CDC Centers for Disease Control and Prevention. Human Factors and
Malaria. 2012.
3. Wipasa J, Suphavilai C, Okell LC, Cook J, Corran PH, Thaikla K, et al. Long-lived
antibody and B cell memory responses to the human malaria parasites.
Plasmodium falciparum and Plasmodium vivax. PLoS Pathog. 2010;6:
e1000770.
4. Krzych U, Dalai S, Zarling S, Pichugin A. Memory CD8T cells specific for
Plasmodia liver-stage antigens maintain protracted protection against
malaria. Front Immunol. 2012;3:370.
5. Stephens R, Langhorne J. Effector memory Th1 CD4 T Cells are maintained
in a mouse model of chronic malaria. PLoS Pathog. 2010;6:e1001208.
6. Ndungu FM, Olotu A, Mwacharo J, Nyonda M, Apfeld J, Mramba LK, et al.
Memory B cells are a more reliable archive for historical antimalarial
responses than plasma antibodies in no-longer exposed children. Proc Natl
Acad Sci U S A. 2012;109:8247–52.
7. Stevenson MM, Ing R, Berretta F, Miu J. Regulating the adaptive immune
response to blood-stage malaria: role of dendritic cells and CD4+Foxp3+
regulatory T cells. Int J Biol Sci. 2011;7:311–22.
8. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al.
Immunobiology of den-dritic cells. Annu Rev Immunol. 2000;18:767–811.
9. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen
processing machines. Cell. 2001;106:255–8.
10. Rescigno M, Borrow P. The host-pathogen interaction: new themes from
dendritic cell biology. Cell. 2001;106:267–70.
11. Urban BC, Ing R, Stevenson MM. Early interactions be-tween blood-stage
Plasmodium parasites and the immune sys-tem. Curr Top Microbiol Immunol.
2005;297:25–70.
12. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate
immune system. Science. 2010;327:291–5.
13. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood.
2008;112:1557–69.
14. Coquerelle C, Moser M. DC subsets in positive and negative regulation of
immunity. Immunol Rev. 2010;234:317–34.
15. Urban BC, Ferguson DJ, Pain A, Willcox N, Plebanski M, Austyn JM, et al.
Plasmodium falciparum-infected erythrocytes modulate the maturation of
dendritic cells. Nature. 1999;400:73–7.
16. Urban BC, Willcox N, Roberts DJ. A role for CD36 in the regulation of
dendritic cell function. Proc Natl Acad Sci U S A. 2001;98:8750–5.
17. Bao LQ, Huy NT, Kikuchi M, Yanagi T, Senba M, Shuaibu MN, et al. CD19(+)
B cells confer protection against experimental cerebral malaria in semi-immune
rodent model. PLoS One. 2013;8:e64836.
Bao et al. Malaria Journal  (2015) 14:23 Page 7 of 718. Evans KJ, Hansen DS, van Rooijen N, Buckingham LA, Schofield L. Severe
malarial anemia of low parasite burden in rodent models results from
accelerated clearance of uninfected erythrocytes. Blood. 2006;107:1192–9.
19. Amani V, Boubou MI, Pied S, Marussig M, Walliker D, Mazier D, et al. Cloned
lines of Plasmodium berghei ANKA differ in their abilities to induce
experimental cerebral malaria. Infect Immun. 1998;66:4093–9.
20. Wykes MN, Kay JG, Manderson A, Liu XQ, Brown DL, Richard DJ, et al.
Rodent blood-stage Plasmodium survive in dendritic cells that infect naive
mice. Proc Natl Acad Sci U S A. 2011;108:11205–10.
21. Wu J, Tian L, Yu X, Pattaradilokrat S, Li J, Wang M, et al. Strain-specific innate
immune signaling pathways determine malaria parasitemia dynamics and
host mortality. Proc Natl Acad Sci U S A. 2014;111:E511–520.
22. Smit JJ, Rudd BD, Lukacs NW. Plasmacytoid dendritic cells inhibit pulmonary
immunopathology and promote clearance of respiratory syncytial virus. J Exp
Med. 2006;203:1153–9.
23. Wykes MN. Are plasmacytoidendritic cells the misguided sentinels of
malarial immunity? Trends Parasitol. 2012;28:182–6.
24. Sponaas AM, Cadman ET, Voisine C, Harrison V, Boonstra A, O'Garra A, et al.
Malaria infection changes the ability of splenic dendritic cell populations to
stimulate antigen-specifi c T cells. J Exp Med. 2006;203:1427–33.
25. Voisine C, Mastelic B, Sponaas AM, Langhorne J. Classical CD11c + dendritic
cells, not plasmacytoid dendritic cells, induce T cell responses to
Plasmodium chabaudi malaria. Int J Parasitol. 2010;40:711–9.
26. Kuwajima S, Sato T, Ishida K, Tada H, Tezuka H, Ohteki T. Interleukin 15–dependent
crosstalk between conventional and plasmacytoid dendritic cells is essential for
CpG-induced immune activation. Nat Immunol. 2006;7:740–6.
27. Millington OR, Di Lorenzo C, Phillips RS, Garside P, Brewer JM. Suppression of
adaptive immunity to heterologous antigens during Plasmodium infection
through hemozoin-induced failure of dendritic cell function. J Biol. 2006;5:5.
28. Dumortier H, van Mierlo GJ, Egan D, van Ewijk W, Toes RE, Offringa R, et al.
Antigen presentation by an immature myeloid dendritic cell line does not
cause CTL deletion in vivo, but generates CD8+ central memory-like T cells
that can be rescued for full effector function. J Immunol. 2005;175:855–63.
29. Haque A, Best SE, Unosson K, Amante FH, de Labastida F, Anstey NM, et al.
Granzyme B expression by CD8+ T cells is required for the development of
experimental cerebral malaria. J Immunol. 2011;186:6148–56.
30. Baptista FG, Pamplona A, Pena AC, Mota MM, Pied S, Vigário AM.
Accumulation of Plasmodium berghei-infected red blood cells in the brain is
crucial for the development of cerebral malaria in mice. Infect Immun.
2010;78:4033–9.
31. McQuillan JA, Mitchell AJ, Ho YF, Combes V, Ball HJ, Golenser J, et al.
Coincident parasite and CD8 T cell sequestration is required for development
of experimental cerebral malaria. Int J Parasitol. 2011;41:155–63.
32. Wykes MN, Good MF. What really happens to dendritic cells during malaria?
Nat Rev Microbiol. 2008;6:864–70.
33. Wykes M, Keighley C, Pinzon-Charry A, Good MF. Dendritic cell biology
during malaria. Cell Microbiol. 2007;9:300–5.
34. Stevenson MM, Ing R, Berretta F, Miu J. Regulating the adaptive immune
response to blood-stage malaria: role of dendritic cells and CD4Foxp3
regulatory T cells. Int J Biol Sci. 2011;7:1311–22.
35. Lundie RJ. Antigen presentation in immunity to murine malaria. Curr Opin
Immunol. 2011;23:119–23.
36. Kumar S, Jones TR, Oakley MS, Zheng H, Kuppusamy SP, Taye A, et al. CpG
oligodeoxynucleotide and montanide ISA 51 adjuvant combination
enhanced the protective efficacy of a subunit malaria vaccine. Infect
Immun. 2004;72:949–57.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
